August 15, 2025GenesOpen Access

Genomics in Lung Cancer: A Scoping Review of the Role of ctDNA in Non-Advanced Non-Small-Cell Lung Cancer in the Prediction of Prognosis After Multimodality Therapeutic Approaches

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Scoping review examines ctDNA's prognostic value in early-stage NSCLC, suggesting potential for clinical integration.

Baseline ctDNA levels provide insights into tumor biology and can influence treatment decisions for early-stage NSCLC.
Evidence supports ctDNA's use as a genomic biomarker in tracking minimal residual disease after surgery and predicting recurrence.
Literature review conducted on 20 studies identified significant links between ctDNA levels and long-term prognosis for NSCLC patients.
Findings indicate that liquid biopsy may improve relapse monitoring compared to traditional methods in managing early-stage NSCLC.

Sassorossi et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark